🐋 AMGN: Someone Just Dropped $26M on a Calendar Roll - Post-Earnings Conviction Play!
February 4, 2026 | 🔥 Unusual Activity Detected
🎯 The Quick Take
A whale just deployed $26 MILLION on AMGN calls using a calendar roll strategy - buying both near-term (Feb 20) and far-dated (April 17) $305 calls simultaneously. This is serious institutional conviction betting on continued upside after yesterday's earnings beat. With AMGN up +12.4% YTD and trading near 52-week highs, someone believes this biotech giant has more room to run!
🏢 Company Overview
| Metric | Details |
|---|---|
| Company | Amgen Inc. (NASDAQ: AMGN) |
| Sector | Biological Products (Biotechnology) |
| Market Cap | $182.3B |
| Current Price | $362.92 (at time of trade) |
| 52-Week Range | $261.43 - $353.25 |
| YTD Performance | +12.4% |
Amgen is a biotechnology heavyweight and global leader in human therapeutics. The company develops blockbuster drugs across oncology, cardiovascular, bone health, and inflammatory diseases. Key franchises include Repatha (cholesterol), Prolia/Evenity (bone health), TEZSPIRE (respiratory), and the newly launched IMDELLTRA (lung cancer). They're also making a big push into the obesity space with MariTide, their monthly-to-quarterly dosing GLP-1 candidate.
💰 The Option Flow Breakdown
📊 What Just Happened
| Time | Direction | Type | Strike | Expiration | Premium | Volume | Spot |
|---|---|---|---|---|---|---|---|
| 11:57:02 | 🟢 BUY | CALL | $305 | 2026-02-20 | $13M | 2,200 | $362.92 |
| 11:57:02 | 🟢 BUY | CALL | $305 | 2026-04-17 | $13M | 2,200 | $362.92 |
Strategy Detected: CALENDAR ROLL 📅
Total Premium Committed: $26,000,000
🔗 Option Chart Links
🤓 What This Actually Means
Let me break this down for you:
The Setup: Someone executed a calendar roll - they're buying calls at the SAME strike ($305) but TWO different expirations. This is NOT your typical directional bet.
Why $305 Strike? These calls are deep in-the-money (~16% ITM with stock at $362.92). The $305 strike gives them:
- 📈 High delta exposure (~0.85-0.90) - moves almost 1:1 with stock
- 🛡️ Intrinsic value of ~$58 per share built in as a cushion
- 💰 Less time decay risk compared to ATM options
The Calendar Angle: By buying both Feb 20 AND April 17 expirations:
- 📊 They're capturing near-term post-earnings momentum (Feb expiry)
- 🎯 While maintaining longer-term exposure through Q1 earnings and MariTide news flow (April expiry)
- ⚖️ This spreads risk across two timeframes - smart money move
Translation for us regular folks: This trader is betting AMGN stays above $305 (basically a lock at current levels) and likely runs higher. The $26M price tag screams institutional - definitely not your neighbor Bob's Robinhood account!
📈 Technical Setup / Chart Check-Up
YTD Performance Chart
AMGN has been on a tear in 2026! The stock started the year at $327.64 and has climbed steadily to current levels around $368, delivering a +12.4% YTD return. The max drawdown has been contained to just -5.08%, showing impressive relative strength.
Key Observations:
- 📈 Strong uptrend since early January
- 💪 Q4 earnings beat on February 3rd sparked the latest leg higher
- 📊 Volume spiking on up days - bullish accumulation pattern
- 🎯 Currently trading near 52-week highs
🟠🔵 Gamma-Based Support & Resistance Analysis
The gamma exposure chart shows where market makers have the most options inventory - these levels act like magnets for price action.
How to read this:
- 🟠 Orange bars (Call Gamma) above price = Resistance levels
- 🔵 Blue bars (Put Gamma) below price = Support levels
- Bigger bars = Stronger levels
Key Gamma Levels:
| Level | Type | Strike | Distance | Strength |
|---|---|---|---|---|
| Strongest Support | 🔵 Support | $365 | -1.0% | Very Strong (GEX: 10.88) |
| Secondary Support | 🔵 Support | $360 | -2.3% | Moderate (GEX: 2.37) |
| Floor Support | 🔵 Support | $350 | -5.0% | Moderate (GEX: 2.61) |
| Immediate Resistance | 🟠 Resistance | $370 | +0.4% | Strong (GEX: 2.40) |
| Next Resistance | 🟠 Resistance | $380 | +3.1% | Moderate (GEX: 0.76) |
| Upside Target | 🟠 Resistance | $390 | +5.8% | Moderate (GEX: 0.67) |
Gamma Summary:
- 📊 Total Call GEX: 23.63 vs Put GEX: 3.93
- 🟢 Net GEX Bias: BULLISH (6x more call gamma than put gamma)
- 🎯 This means dealers are likely short calls - they'll need to BUY stock on rallies, amplifying moves higher
📊 Implied Move Analysis
The options market is pricing in these expected moves:
| Timeframe | Expiry | Days | Implied Move | Price Range |
|---|---|---|---|---|
| Weekly | Feb 6 | 2 | ±1.92% (±$7.05) | $361.32 - $375.43 |
| Monthly OPEX | Feb 20 | 16 | ±3.65% (±$13.45) | $354.92 - $381.83 |
| Triple Witch | Mar 20 | 44 | ±5.43% (±$20.00) | $348.38 - $388.37 |
What This Tells Us:
- 📈 The $305 strike whale bought is WAY below even the bearish monthly scenario ($354.92)
- 🎯 They're not gambling - they're making a high-probability directional bet
- 💡 The Feb 20 upper range ($381.83) and April's potential move to $390+ aligns with resistance levels
🎪 Catalysts
✅ Recent Catalysts (Already Happened)
| Date | Event | Impact |
|---|---|---|
| Feb 3, 2026 | Q4 2025 Earnings Beat | 🟢 EPS $5.29 vs $4.73 est (+11.9% beat), Revenue $9.87B (+8.6% YoY) |
| Feb 3, 2026 | 2026 Guidance Issued | 🟢 Revenue $37-38.4B (above consensus), EPS $21.60-$23.00 |
| Jan 6, 2026 | Dark Blue Acquisition | 🟢 $840M deal for AML pipeline - first pharma M&A of 2026 |
| Jan 2026 | JPM Healthcare Conference | 🟢 CEO called 2026 a "springboard year" |
📅 Upcoming Catalysts
| Date | Event | Potential Impact |
|---|---|---|
| Feb 2026 | Ex-Dividend Date | 🟡 $2.52/share dividend (2.91% yield) |
| Mar 6, 2026 | Dividend Payment | 🟡 Quarterly dividend distribution |
| May 2026 | Q1 2026 Earnings | 🟢 First read on 2026 execution |
| H2 2026 | TEZSPIRE COPD Data | 🟢 Phase 3 results could expand addressable market |
| Q1 2027 | MariTide Phase 3 Data | 🚀 THE BIG ONE - obesity drug readout |
🎲 Price Targets & Probabilities
Based on gamma levels, implied moves, and catalyst analysis:
🐻 Bear Case: $350 (-5.0%)
Probability: 15%
- Scenario: Broader market selloff, biosimilar erosion accelerates, profit-taking after earnings run
- Key level: $350 strike shows strong gamma support - likely floor
- Note: Still well above the $305 whale strike
⚖️ Base Case: $365-$375 (flat to +2%)
Probability: 55%
- Scenario: Stock consolidates post-earnings gains, digests the move
- Gamma magnet at $365 (strongest support) provides floor
- Resistance at $370 may cap near-term upside
- This range aligns with weekly implied move
🚀 Bull Case: $385-$400 (+5% to +8%)
Probability: 30%
- Scenario: Continued momentum, analyst upgrades, broader biotech strength
- Goldman Sachs PT: $415, TD Cowen PT: $420
- April $390 resistance could be tested if momentum continues
- Implied move to $388 by March triple witch supports this target
💡 Trading Ideas
🛡️ Conservative: "The Income Play"
Strategy: Sell Cash-Secured Put at $350 strike, March 20 expiry
- Premium: ~$4-5 per contract
- Max Risk: Buy AMGN at $350 (effective cost basis ~$345)
- Return: ~1.2% in 44 days (10% annualized)
- Why it works: $350 is strong gamma support AND below the bear case target. You either collect premium or buy a quality biotech at a discount.
⚖️ Balanced: "Following the Whale"
Strategy: Buy $360 Call, April 17 expiry
- Cost: ~$15-18 per contract
- Breakeven: ~$375-378
- Target: $390-400 (+50-75% gain on option)
- Why it works: Mirrors the institutional conviction but with less capital at risk. April expiry captures Q1 earnings and potential pipeline news.
🚀 Aggressive: "The Earnings Momentum Play"
Strategy: Buy $375/$390 Call Spread, Feb 20 expiry
- Cost: ~$3-4 per contract
- Max Profit: $15 per contract at $390+ (275% return)
- Breakeven: ~$378
- Why it works: Cheap way to play continued post-earnings momentum. Feb OPEX upper range is $381.83 - this spread profits if we get there.
⚠️ Risk Factors
Market Risks:
- 📉 Broader market correction could drag down biotech sector
- 🎢 Post-earnings profit-taking is common after big beats
- 💊 Drug pricing reform headlines (IRA implementation) could pressure sector
Company-Specific Risks:
- 🧬 Prolia biosimilar erosion accelerating - 6+ competitors launched globally
- 💔 Enbrel declined 33% in 2025 - structural headwinds continue
- ⏳ MariTide Phase 3 data not until Q1 2027 - long wait for major catalyst
- 🏃 Obesity market may be saturated by Novo/Lilly before MariTide launches
Trade-Specific Risks:
- 📊 Options near ATH strikes carry premium risk
- ⏰ Time decay accelerates as Feb expiry approaches
- 💰 $26M whale could be hedging a larger short position (always consider alternatives)
🎯 The Bottom Line
Real talk: Someone with $26 MILLION in conviction just bet on AMGN continuing higher using a sophisticated calendar roll strategy. This isn't speculation - it's calculated positioning by serious institutional money.
The setup is compelling:
- ✅ Q4 earnings crushed it (+11.9% EPS beat)
- ✅ 2026 guidance above Street expectations
- ✅ Growth products firing (Repatha +36%, TEZSPIRE +52%, Evenity +34%)
- ✅ Gamma profile strongly bullish (6x call vs put exposure)
- ✅ Stock showing relative strength (+12.4% YTD)
The risks are real but manageable:
- ⚠️ Trading near 52-week highs
- ⚠️ Biosimilar headwinds on legacy products
- ⚠️ MariTide catalyst is 12+ months away
📋 Action Plan:
If you're bullish: Consider the balanced strategy - April $360 calls give you exposure through Q1 with defined risk. The whale's $305 deep ITM approach is too capital-intensive for most retail traders.
If you're watching: Wait for a pullback to the $360-365 gamma support zone before establishing positions. That's where the smart money would add.
If you're cautious: Sell puts at the $350 level - you either get paid to wait or buy a quality biotech at a 5% discount to current levels.
Mark your calendar: Q1 2026 earnings in early May will be the next major test. Until then, ride the post-earnings momentum but respect the $370 resistance.
Disclaimer: Options trading involves significant risk and is not suitable for all investors. The analysis above is for educational purposes only and should not be considered investment advice. The unusual options activity discussed may represent hedging activity rather than directional bets. Always conduct your own due diligence and consider your risk tolerance before trading.
Data sources: Amgen Q4 2025 Earnings, MarketBeat, Investing.com, Seeking Alpha
Analysis generated February 4, 2026 | View AMGN on Ainvest